J-Lat 10.6 cell line treated with either DMSO, 10µM compound 4, or 10µM compound 16 for 24 h.

Human immunodeficiency virus (HIV) still remains a major global public health issue. Combination antiretroviral therapy (ART) is effective to reduce the morbidity and mortality of HIV infected patients. However, ART is unable to eradicate HIV due to the establishment of long-lived and proliferating HIV latently infected cells. Once ART is stopped, these cells will drive resurgence of the infection. Hence, ART in combination with HIV latency reversing agents (LRAs), which target signaling pathways involved in HIV transcription, has become an approach to target and eliminate HIV latency. Here, we identified two compounds with novel structures possessing HIV latency reversing activity. They are named compound 4 and 16, respectively. To understand their underlying mechanism, we carried out RNA-seq for J-Lat 10.6 cells treated with either DMSO, 10µM compound 4, or 10µM compound 16 for 24 h. Overall design: RNA-seq profiling for J-Lat 10.6 cells treated with either DMSO, 10µM compound 4, or 10µM compound 16 for 24 h.